BR112017013440A2 - compostos de isoquinolina para o tratamento de hiv - Google Patents

compostos de isoquinolina para o tratamento de hiv

Info

Publication number
BR112017013440A2
BR112017013440A2 BR112017013440-3A BR112017013440A BR112017013440A2 BR 112017013440 A2 BR112017013440 A2 BR 112017013440A2 BR 112017013440 A BR112017013440 A BR 112017013440A BR 112017013440 A2 BR112017013440 A2 BR 112017013440A2
Authority
BR
Brazil
Prior art keywords
hiv
treatment
compounds
isoquinoline compounds
isoquinoline
Prior art date
Application number
BR112017013440-3A
Other languages
English (en)
Inventor
Jansa Petr
L. Mackman Richard
Eric Hu Yunfeng
Lansdon Eric
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of BR112017013440A2 publication Critical patent/BR112017013440A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a compostos de fórmula (i) e tautômeros e sais farmacêuticos dos mesmos, composições e formulações contendo tais compostos, e métodos de uso e fabricação de tais compostos.
BR112017013440-3A 2014-12-24 2015-12-23 compostos de isoquinolina para o tratamento de hiv BR112017013440A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462096769P 2014-12-24 2014-12-24
US62/096,769 2014-12-24
PCT/US2015/000310 WO2016105534A1 (en) 2014-12-24 2015-12-23 Isoquinoline compounds for the treatment of hiv

Publications (1)

Publication Number Publication Date
BR112017013440A2 true BR112017013440A2 (pt) 2018-01-09

Family

ID=55168341

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013440-3A BR112017013440A2 (pt) 2014-12-24 2015-12-23 compostos de isoquinolina para o tratamento de hiv

Country Status (17)

Country Link
US (1) US9624195B2 (pt)
EP (1) EP3237397B1 (pt)
JP (1) JP6356919B2 (pt)
KR (1) KR101960624B1 (pt)
CN (1) CN107428693B (pt)
AU (1) AU2015371257B2 (pt)
BR (1) BR112017013440A2 (pt)
CA (1) CA2972017C (pt)
EA (1) EA201791304A1 (pt)
ES (1) ES2705709T3 (pt)
HK (2) HK1244271B (pt)
IL (1) IL253052A0 (pt)
MX (1) MX2017008518A (pt)
NZ (1) NZ733125A (pt)
PT (1) PT3237397T (pt)
SG (1) SG11201705184PA (pt)
WO (1) WO2016105534A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
CN107207498B (zh) 2014-12-24 2020-03-24 吉利德科学公司 用于治疗hiv的稠合嘧啶化合物
CA2972259A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
AU2021377614A1 (en) 2020-11-11 2023-06-22 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
WO2023102529A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TW202342447A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
AU2022401696A1 (en) 2021-12-03 2024-05-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197420A (en) 1980-07-01 1984-04-27 Ici Australia Ltd -(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
EP1218358B1 (en) * 1999-09-23 2006-09-13 AstraZeneca AB Therapeutic quinazoline compounds
WO2001038315A1 (en) 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
JP2004505110A (ja) 2000-08-02 2004-02-19 セルテック　アール　アンド　ディ　リミテッド ３位置換イソキノリン−１−イル誘導体
AU2001293817A1 (en) 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
GB0217015D0 (en) 2002-07-23 2002-08-28 Bioacta Ltd Peptide 4
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
WO2004108711A1 (en) 2003-06-05 2004-12-16 Astrazeneca Ab Pyrazinil quinazoline derivatives for use in the treatment of tumours
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
PT2258376T (pt) 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101048410B (zh) 2004-10-29 2010-06-23 泰博特克药品有限公司 抑制hiv的双环嘧啶衍生物
KR20060079121A (ko) 2004-12-31 2006-07-05 에스케이케미칼주식회사 당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체
WO2006099301A2 (en) 2005-03-10 2006-09-21 The Regents Of The University Of California Apoptosis inhibitors
JP5079500B2 (ja) 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
BRPI0613597A2 (pt) 2005-06-28 2011-01-18 Sanofi Aventis derivado de isoquinolina como inibidores de rho-quinase
PT1910333E (pt) 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
MX2008009581A (es) * 2006-01-27 2009-01-07 Fibrogen Inc Compuestos de cianoisoquinolina que estabilizan el factor inducible hipoxia (fih).
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
AU2007275682B2 (en) 2006-07-20 2012-05-17 Amgen Inc. Substituted pyridone compounds and methods of use
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2008050808A1 (fr) 2006-10-24 2008-05-02 Kyowa Hakko Kirin Co., Ltd. Dérivé de 2-aminoquinazoline
MY150746A (en) 2006-12-27 2014-02-28 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
CN101595094B (zh) 2006-12-27 2013-02-20 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹诺酮衍生物
WO2008077553A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives
WO2008086462A2 (en) 2007-01-11 2008-07-17 Wyeth AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
EP2144908A1 (en) 2007-04-06 2010-01-20 Novartis Ag 2, 6-naphthyridine derivatives as protein kinase modulators
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
UA100250C2 (uk) 2007-11-16 2012-12-10 Гілеад Сайнсіз, Інк. Інгібітори реплікації вірусу імунодефіциту людини
WO2009131173A1 (ja) 2008-04-23 2009-10-29 協和発酵キリン株式会社 2-アミノキナゾリン誘導体
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
EP2315627B1 (de) 2008-08-15 2014-10-15 Basf Se Verfahren zur herstellung von nanoskaligen organischen feststoffpartikeln
PT2364314E (pt) 2008-12-09 2014-06-09 Gilead Sciences Inc Moduladores de recetores toll-like
EA019110B1 (ru) 2008-12-29 2014-01-30 Фовеа Фармасьютикалз Замещенные хиназолиновые соединения
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2011035416A1 (en) 2009-09-25 2011-03-31 Aegera Therapeutics Inc. Hsp90 modulating compounds, compositions, methods and uses
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
WO2011163610A2 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
EA201291301A1 (ru) 2010-07-02 2013-05-30 Джилид Сайэнс, Инк. Производные 2-хинолинилуксусной кислоты в качестве противовирусных соединений против вич
PE20130385A1 (es) 2010-07-02 2013-03-30 Gilead Sciences Inc Derivados del acido naft-2-ilacetico para tratar el sida
WO2012044090A2 (ko) 2010-09-29 2012-04-05 크리스탈지노믹스(주) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
KR20120038060A (ko) 2010-10-13 2012-04-23 롬엔드하스전자재료코리아유한회사 신규한 유기 전자재료용 화합물 및 이를 포함하는 유기 전계 발광 소자
JP6026427B2 (ja) 2010-12-17 2016-11-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換６，６−縮合窒素複素環化合物及びその使用
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
WO2012145728A1 (en) 2011-04-21 2012-10-26 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
JP6144698B2 (ja) 2011-12-20 2017-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｉｖ複製の阻害剤としての縮合三環式化合物
EP2788336B1 (en) 2012-04-20 2016-03-02 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
SG11201504857SA (en) 2012-12-21 2015-07-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US20140221380A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
EP2769722A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
EP2769723A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
US9914709B2 (en) 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
CN107207498B (zh) 2014-12-24 2020-03-24 吉利德科学公司 用于治疗hiv的稠合嘧啶化合物
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv

Also Published As

Publication number Publication date
MX2017008518A (es) 2017-10-25
ES2705709T3 (es) 2019-03-26
KR101960624B1 (ko) 2019-03-20
EA201791304A1 (ru) 2017-12-29
JP2018500356A (ja) 2018-01-11
CN107428693A (zh) 2017-12-01
NZ733125A (en) 2018-06-29
CA2972017C (en) 2019-06-11
US20160237062A1 (en) 2016-08-18
SG11201705184PA (en) 2017-07-28
HK1246776A1 (zh) 2018-09-14
CA2972017A1 (en) 2016-06-30
PT3237397T (pt) 2019-02-08
AU2015371257A1 (en) 2017-07-13
EP3237397B1 (en) 2018-11-21
IL253052A0 (en) 2017-08-31
AU2015371257B2 (en) 2018-09-06
CN107428693B (zh) 2020-05-29
EP3237397A1 (en) 2017-11-01
KR20170096049A (ko) 2017-08-23
US9624195B2 (en) 2017-04-18
JP6356919B2 (ja) 2018-07-11
HK1244271B (zh) 2019-11-29
WO2016105534A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
BR112016015365A8 (pt) composto, composição farmacêutica e uso de um composto
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2017014035A (es) Formas solidas novedosas.
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
MX2021003792A (es) Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
TW201613864A (en) Novel compounds
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
BR112017004000A2 (pt) formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
CL2012001964A1 (es) Uso de compuestos multiciclicos seleccionados de ingenoles, lanosta-8,24-dien-3-oles y sus mezclas para la produccion de composiciones farmaceuticas para la prevencion o tratamiento de infecciones de vih.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements